Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yisheng Biopharma Granted US Orphan Drug Status for Immunotherapy

publication date: Feb 26, 2018

Yisheng Biopharma, a Beijing immunological/vaccine company, was granted US Orphan Drug Designation for its lead oncology molecule, YS-ON-001, as a treatment for pancreatic cancer. It was the third ODD for YS-ON-001, following ODDs for pancreatic cancer and hepatocellular carcinoma. According to Yishing, YS-ON-001 works by affecting the tumor microenvironment. The company says the candidate produced "breakthrough" effects in preclinical tests, better than a PD-1 molecule, and synergistic effects in combination with the company's own PD-1 drug. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here